ArticleFrontiers in microbiology2025
Integrated analysis of fecal microbiota and metabolomics reveals unique characteristics of asymptomatic and classic celiac disease.
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Supernatants of Water Extraction-Ethanol Precipitation from Roots ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Early-life gastrointestinal inflammation and the developing brain: Unravelling the pathways to long-term cognitive dysfunction.World journal of clinical pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Celiac Disease (CeD) is an autoimmune small intestinal disorder triggered by gluten, with clinical subtypes including typical, atypical, and asymptomatic forms.While classic CeD development is linked to microbes/metabolites, their relationships with other subtypes remain unclear. Methods: We conducted 16S rDNA sequencing on fecal samples from 14 asymptomatic CeD (SCeD) patients and integrated this data with our team's prior sequencing data of 30 classic CeD (CDF) patients and 30 healthy controls (CDFH). Results: 16S rDNA results showed: Compared to CDFH, SCeD had lower abundances of Bacteroides, Alistipes, CAG-352 and higher abundances of Blautia, Collinsella, Dorea, Mediterraneibacter, Gemmiger; a random forest model based on 8 differential microbes distinguished SCeD from CDFH (AUC = 0.97). Compared to CDF, SCeD had lower Bacteroides and higher Faecalibacterium, Blautia, Collinsella, Agathobacter-suggesting Bacteroides may relate to CeD symptoms, while Faecalibacterium and Agathobacter may alleviate symptoms. Metabolomic analysis identified differential metabolites between SCeD and CDFH (enriched in "Steroid Hormone Biosynthesis," "Primary Bile Acid Biosynthesis," "Tryptophan Metabolism" via KEGG) and between SCeD and CDF (enriched in "Tryptophan Metabolism," "Biosynthesis of Plant Secondary Metabolites," "Degradation of Flavonoids"). Spearman analysis showed correlations between differential microbes and metabolites. Discussion: In conclusion, different CeD subtypes may involve a "host-microbe-metabolite" trinity network: A random forest model built with SCeD-CDFH differential microbes/metabolites is a high-efficacy SCeD diagnostic tool; modulating these microbes/metabolites could be a new entry point for CeD mechanism research and adjunctive therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.